Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ERO1a fosters glioblastoma aggressiveness and metabolic flexibility by regulating mitochondria-associated membrane dynamics.

Nature cell biology·2026
Same author

Unveiling the molecular architecture of T cells and immune synapses with cryo-expansion microscopy.

Cell reports·2026
Same author

MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion.

The Journal of experimental medicine·2026
Same author

Lipidomic profiling of extracellular vesicles from breast and metastatic triple-negative breast cancer cell lines for identification of potential biomarkers.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.

iScience·2026
Same author

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Molecular oncology·2026

Related Experiment Video

Updated: Mar 6, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

[Brain tumor immunotherapy: Illusion or hope?]

Denis Migliorini1, Valérie Dutoit1, Paul R Walker1

  • 1Hôpitaux universitaires de Genève, centre d'oncologie, 4, rue Gabrielle-Perret-Gentil, 1211 Genève, Suisse.

Bulletin Du Cancer
|March 21, 2017
PubMed
Summary

Brain tumor immunotherapy shows promise with new immune checkpoint inhibitors like anti-CTLA-4 and PD1. Research is exploring complex strategies and therapies targeting the tumor microenvironment to overcome brain tumor challenges.

Keywords:
GliomaGliomesImmunotherapyImmunothérapieMicro-environnementMicroenvironment

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K

Related Experiment Videos

Last Updated: Mar 6, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Immunotherapy is a standard cancer treatment for many tumors.
  • Brain tumors present unique challenges due to their immunosuppressive tumor microenvironment.
  • Recent advancements in immune checkpoint inhibitors offer new hope for brain tumor treatment.

Purpose of the Study:

  • To review the current landscape of brain tumor immunotherapy.
  • To discuss the challenges and potential of immunotherapies for brain tumors.
  • To provide an overview of ongoing clinical research, focusing on tumor microenvironment-targeted therapies.

Main Methods:

  • Review of recent developments in immunotherapy, including immune checkpoint inhibitors (anti-CTLA-4, PD1).
  • Exploration of advanced immunotherapeutic models such as vaccination and adoptive T cell transfer.
  • Investigation of therapies aimed at modulating the brain tumor microenvironment.

Main Results:

  • Anti-CTLA-4 and PD1 inhibitors can restore T lymphocyte activity, showing therapeutic potential.
  • The brain tumor microenvironment is highly immunosuppressive, posing significant hurdles.
  • Early-phase trials are investigating novel strategies to reshape this microenvironment.

Conclusions:

  • Despite challenges, immunotherapy holds significant promise for brain tumors.
  • Targeting the tumor microenvironment is a critical area of ongoing research.
  • Further clinical investigation is essential to realize the full potential of brain tumor immunotherapy.